CDXS:NSD-Codexis, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 25.57

Change

-0.83 (-3.14)%

Market Cap

USD 1.68B

Volume

0.68M

Average Target Price

USD 29.00 (+13.41%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Codexis, Inc. discovers, develops, and sells protein catalysts. It offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering protein catalysts that perform chemical transformations. The company's platform is used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. Its platform also enhances the pharmaceuticals companies manufacturing productivity and efficiency or outsourcing the manufacture of the intermediates and active pharmaceutical ingredients. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.

Company Website : http://www.codexis.com

Address : 200 Penobscot Drive, Redwood City, CA, United States, 94063

Employees : 161

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.17

52 Week High : 27.10

Short Ratio : 7.52

52 Week Low : 8.43

Shorted Shares : 6,023,710

200 Day Moving Average : 15.21

Shorted Shares Previous Month : 4,619,714

50 Day Moving Average : 20.97

Shares Held By Insiders : 30.74%

Short Percentage : 9.00%

Shares Held by Institutions : 85.59%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-20 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+4.79 (+2.07%)

 USD60.31B 22.73 18.26
REGN Regeneron Pharmaceuticals, Inc

+8.38 (+1.57%)

 USD56.97B 19.57 14.64
MRNA Moderna, Inc

+0.13 (+0.10%)

 USD49.47B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

-0.97 (-0.61%)

 USD34.71B 36.83 33.83
SGEN Seagen Inc

+2.02 (+1.07%)

 USD33.79B 71.29 70.76
RPRX Royalty Pharma plc

-1.50 (-2.89%)

 USD32.42B 22.60 11.90
BGNE BeiGene, Ltd

+6.12 (+1.72%)

 USD32.06B N/A N/A
GMAB Genmab A/S

-1.07 (-2.41%)

 USD28.72B 26.59 3.08
BNTX BioNTech SE

-1.47 (-1.40%)

 USD25.21B -99,999.99 N/A
INCY Incyte Corporation

+2.41 (+2.56%)

 USD20.58B 47.64 35.20

ETFs Containing CDXS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 17.13% 60% D- 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.13% 60% D- 77% C+
Trailing 12 Months  
Capital Gain 46.11% 62% D- 72% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 46.11% 62% D- 72% C-
Trailing 5 Years  
Capital Gain 523.66% 91% A- 92% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 523.66% 91% A- 92% A-
Average Annual (5 Year Horizon)  
Capital Gain 52.06% 80% B- 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 52.06% 80% B- 90% A-
Risk Return Profile  
Volatility (Standard Deviation) 76.05% 33% F 15% F
Risk Adjusted Return 68.46% 91% A- 83% B
Market Capitalization 1.68B 79% C+ 71% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 16.30 12% F 9% F
Price / Cash Flow Ratio -133.61 97% A+ 96% A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -21.44% 86% B 34% F
Return on Invested Capital -15.53% 85% B 30% F
Return on Assets -9.21% 87% B+ 28% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 7.52 21% F 14% F
Short Percent 9.74% 34% F 22% F
Beta 1.17 69% D+ 51% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.